Pixantrone
98%
- Product Code: 102066
CAS:
144510-96-3
| Molecular Weight: | 325.37 g./mol | Molecular Formula: | C₁₇H₁₉N₅O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Pixantrone is primarily used in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). It is administered intravenously and works by inhibiting topoisomerase II, an enzyme critical for DNA replication and cell division, thereby preventing the proliferation of cancer cells. Its unique structure reduces the risk of cardiotoxicity compared to other anthracyclines, making it a safer option for patients with pre-existing heart conditions. Pixantrone is often considered when other treatments have failed, offering a therapeutic alternative for patients with limited options. It is typically used in combination with other chemotherapeutic agents to enhance its efficacy. Clinical studies have shown improved response rates and progression-free survival in patients receiving pixantrone-based regimens.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Brown To Dark Brown Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿8,880.00 |
+
-
|
| 0.050 | 10-20 days | ฿29,800.00 |
+
-
|
| 0.100 | 10-20 days | ฿56,000.00 |
+
-
|
Pixantrone
Pixantrone is primarily used in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). It is administered intravenously and works by inhibiting topoisomerase II, an enzyme critical for DNA replication and cell division, thereby preventing the proliferation of cancer cells. Its unique structure reduces the risk of cardiotoxicity compared to other anthracyclines, making it a safer option for patients with pre-existing heart conditions. Pixantrone is often considered when other treatments have failed, offering a therapeutic alternative for patients with limited options. It is typically used in combination with other chemotherapeutic agents to enhance its efficacy. Clinical studies have shown improved response rates and progression-free survival in patients receiving pixantrone-based regimens.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :